Literature DB >> 30174924

Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Alessio Cortellini1,2, Antonella Dal Mas3, Katia Cannita1, Guido Collina4, Alessandro Parisi1,2, Francesco Pavese1,2, Giampiero Porzio1,2, Lucilla Verna2, Corrado Ficorella1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30174924      PMCID： PMC6105959          DOI： 10.21037/jtd.2018.06.44

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  33 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer.

Authors:  Taofeek K Owonikoko; Madhusmita Behera; Zhengjia Chen; Chandar Bhimani; Walter J Curran; Fadlo R Khuri; Suresh S Ramalingam
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

3.  Second line treatment of small cell lung cancer: more is better?

Authors:  Michael S Humeniuk; Michael John Kelley
Journal:  Ann Transl Med       Date:  2016-10

Review 4.  Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Authors:  David R Spigel; Mark A Socinski
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

5.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Authors:  Mary E R O'Brien; Tudor-Eliade Ciuleanu; Hristo Tsekov; Yaroslav Shparyk; Branka Cuceviá; Gabor Juhasz; Nicholas Thatcher; Graham A Ross; Graham C Dane; Theresa Crofts
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

6.  Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.

Authors:  M Catherine Pietanza; Kyuichi Kadota; Kety Huberman; Camelia S Sima; John J Fiore; Dyana K Sumner; William D Travis; Adriana Heguy; Michelle S Ginsberg; Andrei I Holodny; Timothy A Chan; Naiyer A Rizvi; Christopher G Azzoli; Gregory J Riely; Mark G Kris; Lee M Krug
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

7.  Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents.

Authors:  A Bearzatto; M Szadkowski; P Macpherson; J Jiricny; P Karran
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

8.  Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.

Authors:  Marta Brell; Avelina Tortosa; Eugenia Verger; Juan Miguel Gil; Nuria Viñolas; Salvador Villá; Juan José Acebes; Lluis Caral; Teresa Pujol; Isidro Ferrer; Teresa Ribalta; Francesc Graus
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

9.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

10.  Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma.

Authors:  C De Divitiis; C von Arx; A M Grimaldi; D Cicala; F Tatangelo; A Arcella; G M Romano; E Simeone; R V Iaffaioli; P A Ascierto; S Tafuto
Journal:  J Transl Med       Date:  2016-05-03       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.